PKI Stock Recent News
PKI LATEST HEADLINES
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.03% and 30.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Parkland Corporation (OTCPK:PKIUF) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Valerie Roberts - Director, Investor Relations Bob Espey - President and CEO Marcel Teunissen - Chief Financial Officer Conference Call Participants Michael Van Aelst - TD Securities Ben Isaacson - Scotiabank Carly Davenport - Goldman Sachs Steve Hansen - Raymond James Matthew Weekes - iA Capital Markets Peter Sklar - BMO Operator Good morning. My name is Marcella, and I will be the operator assisting you today.
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PerkinElmer said Monday it expects organic sales and adjusted profit to top its previous third-quarter expectations, and PKI stock jumped. The post PerkinElmer Sweetens Its Outlook And Shares Surge, But There's Still One Hitch appeared first on Investor's Business Daily.
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
PerkinElmer, Inc. (NYSE:PKI ) Baird's 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson - Baird Tom Peterson Thanks, everyone. Welcome. Thank you for joining.
PerkinElmer has sold a substantial business in recent times, in order to fully focus on life science and diagnostic activities. The deal looks a bit cheap but is likely okay in the long run.